Arzeda Raises $12 Million in Series A Round of Funding Led by OS Fund
Arzeda, The Protein Design Company™, today announced that it had raised $12 million in a Series A round of funding led by OS Fund and including Bioeconomy Capital and Sustainable Conversion Ventures, as well as a follow-on investment from Arzeda’s seed investor, WRF Capital. Arzeda’s board will be expanded to include Jeff Klunzinger, Co-Founder at OS Fund.
Gen9 and Arzeda Announce Supply Agreement for Synthetic DNA
Gen9 and Arzeda today announced an agreement for the supply of megabase quantities of synthetic DNA that will enable Arzeda to accelerate development of novel molecules for its own products as well as those of its partners. The collaboration is part of Gen9’s MAP program, designed to provide industrial users of synthetic DNA with access to game-changing economics for synthetic DNA.
Arzeda and Zymergen Collaborate on Development of New Molecules
Zymergen and Arzeda announced today a multi-year agreement to develop strains and processes to manufacture novel, high utility molecules and materials utilizing Arzeda’s pathway and enzyme design and Zymergen’s strain construction capabilities. “The development of new materials was a major driver of technological development over the course of the 20th century. Biology has the potential to drive materials breakthroughs in the 21st century, and Arzeda’s technology can help identify new
Arzeda Agreement with Stratos Genomics for Novel Enzyme Development
Biotechnology company Arzeda announced today an Agreement with Stratos Genomics to assist development of novel enzymes supporting Stratos’ DNA sequencing technology.
